Search results
Showing 1096 to 1110 of 1559 results for do not do recommendations
Coronary sinus narrowing device implantation for refractory angina (HTG600)
Evidence-based recommendations on coronary sinus narrowing device implantation for refractory angina in adults. This involves putting a device into the coronary sinus to narrow it with the aim of improving the flow of oxygenated blood throughout the heart muscle.
View recommendations for HTG600Show all sections
Evidence-based recommendations on subcutaneous automated low-flow pump implantation for refractory ascites in adults. This involves inserting a pump under the skin to move excess fluid from the abdomen to the bladder, where it is passed in the urine.
View recommendations for HTG490Show all sections
Early value assessment (EVA) guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments.
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.
Low-energy contact X-ray brachytherapy for rectal cancer (HTG763)
Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.
Evidence-based recommendations on radiofrequency treatment for haemorrhoids in adults. This involves using radiofrequency energy to shrink the haemorrhoids.
Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (HTG339)
Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. This involves dividing appropriate parts of the sympathetic chain beside the vertebral column to reduce sweating.
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.
Ustekinumab for treating moderate to severe plaque psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.
Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Endo-SPONGE for treating low rectal anastomotic leak (HTG605)
Evidence-based recommendations on Endo-SPONGE for treating low rectal anastomotic leak.
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.